Dr. Bienvenue joined Good Therapeutics in 2021 with 19 years of biotech experience and serves as Senior Director of Protein Sciences. Most recently, he served as Vice President of Protein Sciences, Analytical and Process Development at Aptevo Therapeutics. He led the Aptevo Early Product Development Team to develop novel bispecific proteins for immuno-oncology and is an inventor on multiple Aptevo patents. His approach to clinical lead selection emphasizes the importance of evaluating both function and developability during preclinical research.
Dr. Bienvenue also held positions as Director of Protein Sciences at VLST Corporation and downstream development lead at Dendreon Corporation. At Dendreon, he participated in the development of Provenge®, the first FDA-approved immunotherapy for prostate cancer. He obtained his PhD in Biochemistry from Utah State University.